The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women
- PMID: 11751447
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women
Abstract
The enzyme 5alpha-reductase type II (SRD5A2) converts testosterone to its more active form 5alpha-dihydroxytestosterone. The 3' untranslated region of the gene contains a (TA)(n) length polymorphism. The (TA)(9) allele has been reported to be associated with higher serum prostate-specific antigen levels in breast tumors and lower risk of relapse in breast cancer patients and more recently has also been reported to be linked to the codon 89 valine variant, which is itself associated with higher serum prostate-specific antigen levels in breast tumors and a more favorable breast cancer prognosis. We investigated whether the SRD5A2 (TA)(n) polymorphism was associated with risk of breast or ovarian cancer in Australian women by studying 946 breast cancer cases and 509 age-matched controls, and 544 ovarian cancer cases and 298 controls of similar age distribution. The (TA)(9) allele frequency was similar in breast cancer cases (0.110), breast cancer controls (0.125), ovarian cancer cases (0.106), and ovarian cancer controls (0.117). There was no difference in genotype distribution between breast cancer cases and controls (P = 0.5), ovarian cancer cases and controls (P = 0.7), or between the two control groups (P = 0.9). Genotypes containing at least one (TA)(9) allele were not significantly associated with risk of breast cancer overall (odds ratio, 0.86; 95% confidence interval, 0.67-1.12; P = 0.3) or in women stratified by age, menopausal status, or family history. Similarly, the (TA)(9) allele was not associated with risk of ovarian cancer (odds ratio, 0.87; 95% confidence interval, 0.61-1.23; P = 0.4) or with ovarian tumor behavior (invasive or low malignant potential), histology, stage, or grade. Given that this study had sufficient power to detect altered risks in the order of 1.4- to 1.7-fold, our results suggest that the SRD5A2 (TA)(9) allele is unlikely to be associated with moderate alterations in breast or ovarian cancer risk.
Similar articles
-
TA repeat polymorphism of the 5alpha-reductase gene and breast cancer.Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):387-93. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 10794483
-
Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1077-82. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11588134
-
The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1194-9. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14652280
-
Genetic epidemiology of breast cancer in younger women.J Natl Cancer Inst Monogr. 1994;(16):49-53. J Natl Cancer Inst Monogr. 1994. PMID: 7999469 Review.
-
Etiology of cancer of the human ovary: a review.J Natl Cancer Inst. 1974 Dec;53(6):1603-18. J Natl Cancer Inst. 1974. PMID: 4612161 Review.
Cited by
-
Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.BMC Cancer. 2003 Mar 22;3:9. doi: 10.1186/1471-2407-3-9. BMC Cancer. 2003. PMID: 12659654 Free PMC article.
-
Association of V89L SRD5A2 polymorphism with craving and serum leptin levels in male alcohol addicts.Psychopharmacology (Berl). 2012 Dec;224(3):421-9. doi: 10.1007/s00213-012-2770-5. Epub 2012 Jun 17. Psychopharmacology (Berl). 2012. PMID: 22707254
-
Current understanding of risk factors for ovarian cancer.Curr Treat Options Oncol. 2009 Apr;10(1-2):67-81. doi: 10.1007/s11864-009-0108-2. Epub 2009 Jul 15. Curr Treat Options Oncol. 2009. PMID: 19603272 Review.
-
Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients.Eur J Cancer. 2008 Oct;44(15):2259-65. doi: 10.1016/j.ejca.2008.07.010. Epub 2008 Aug 22. Eur J Cancer. 2008. PMID: 18723338 Free PMC article.
-
Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide.Appl Clin Genet. 2020 Apr 14;13:83-96. doi: 10.2147/TACG.S198178. eCollection 2020. Appl Clin Genet. 2020. PMID: 32346305 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Molecular Biology Databases